Herein we found that TFD and FFD are therapeutic against the DSS-induced murine IBD model, illustrated through reduced clinical symptoms of IBD, decreased secretion of IL-6 and IL-1β, decreased intestinal inflammation, and reduced p-p65 and p-IĸB-α expression levels in both dextran sulfate sodium (DSS)- and 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced experimental IBD mice. The gene discussed is IL6; the disease is inflammatory bowel disease.